Abstract 533: Accurately identifying expressed somatic variants for neoantigen detection and immuno-oncology
Authors: Boyle Sean M. , Clark Michael J. , Alla Ravi , Luo Shujun , Church Deanna M. , Helman Elena , Sripakdeevong Parin , West John , Chen Rich 
Published: July 2016

Abstract
Accurate detection of somatic variants is a staple of both research and clinical cancer analysis, with applications ranging from detecting new common driver mutations in large patient cohorts to selecting therapeutic small molecule treatment courses for an individual patient. Recent research into neoantigens and immunotherapy has shown great promise as a precision therapeutic, and somatic variant detection by next-generation sequencing represents an ideal method of identifying candidate neoantigens. Somatic variant detection typically involves assaying the DNA for changes in gene sequences without assessing whether those variants are actually expressed in RNA. However, the expression of small variants is key because only expressed peptides will be displayed as neoantigens on the cell surface.
From a technical standpoint, detection of somatic variants in the RNA represents additional challenges above and beyond those of somatic detection in DNA. The widely varying expression levels of cancer genes, alternative splicing, and RNA editing are all features that make somatic variant calling in RNA uniquely challenging. However, accurately detecting variants directly from expressed transcripts is beneficial to neoantigen prediction, and therefore we sought to create and validate a method for somatic variant calling in RNA.
We have designed a highly accurate expression-based somatic variant detection pipeline utilizing extensive discovery and filtering methods to overcome the challenges inherent in RNA somatic variant calling. We validated our pipeline using a combination of well-characterized cell lines, commercially available reference standards, and real world FFPE patient samples. To our knowledge, this is the most extensive validation of its kind to date, representing over 29,158 small variants across 39 samples. In testing, we measured our detection method at &gt;99% sensitivity and &gt;99% PPV using a combination of gold set small variants and orthogonal validation. This method, in combination with our validated DNA somatic variant calling pipeline (&gt;99% sensitivity and &gt;99% PPV), enables precise detection of variant expression levels in a given sample, even at low allele frequency (5%).
After validating our RNA somatic variant calling method, we applied it to detect candidate neoantigens in patient tumor samples. We performed HLA typing for each sample using HLAssign software and predicted MHC presentation of the expressed somatic variants. In ongoing studies, we are validating our most promising putative neoantigens using orthogonal technologies and demonstrating our ability to detect the most promising clinically effective peptides for therapy.
Citation Format: Sean M. Boyle, Michael J. Clark, Ravi Alla, Shujun Luo, Deanna M. Church, Elena Helman, Parin Sripakdeevong, John West, Rich Chen. Accurately identifying expressed somatic variants for neoantigen detection and immuno-oncology. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 533.